X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Fertin Pharma AS
Deal Size: $820.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 15, 2021
Details:
OtiTopic develops the Asprihale patented dry powder inhalation ASA treatment to treat acute myocardial infarction as a self-administered aerosol. The company expects to move from clinical trials of Asprihale to filing for FDA approval at some point in 2022.
Lead Product(s): Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Asprihale
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: OtiTopic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 09, 2021
Details:
Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Fertin Pharma AS
Deal Size: $820.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
